Endometriosis and hair loss: investigate the cause without assuming a direct link

What the research actually connects

Endometriosis involves tissue resembling the womb lining growing outside the womb. Symptoms can include pelvic pain, painful or heavy periods, fatigue and difficulty conceiving. They vary between individuals, and not everyone experiences all of them. Thinning hair cannot identify endometriosis or indicate how extensive the condition is, even when the two concerns arise around the same time.

Some research has examined associations with particular skin conditions. In 2025, Sakiyama and colleagues compared 835 adults with endometriosis with 309 women without that diagnosis. Alopecia areata was reported more often in the endometriosis group. Recruitment partly involved online groups, with many skin complaints not directly verified; participants were not randomly selected for the comparison.

This cross-sectional study cannot establish which condition developed first or prove that endometriosis causes alopecia areata. It also did not examine every form of hair loss. Alopecia areata is a particular disorder, distinct from generally increased shedding during washing. Turning this result into an overall percentage of people losing hair because of endometriosis would therefore misrepresent the findings.

Endometriosis and polycystic ovary syndrome are also different diagnoses. Having the former does not establish androgen excess or justify using treatment intended for the latter. Any endocrine features need assessment in their own right. Our article on hormonal factors in hair loss explains why a blood hormone measurement cannot give a complete account of a person’s hair changes.

An inflammatory condition may share possible biological mechanisms with another disorder without explaining every case of it. Such hypotheses guide research rather than identifying your diagnosis or the treatment you should try. The practical message is to take a dermatological concern seriously in someone receiving endometriosis care, instead of presenting hair loss as an unavoidable consequence of the condition.

Reconstruct the timing within a long treatment history

The onset of endometriosis, its eventual diagnosis and the beginning of hair loss may be separated by years. Shedding noticed after receiving the diagnosis did not necessarily start with the disease. Record roughly when your hair changed and what preceded it: a new medicine, a change in contraception, surgery, a feverish illness or difficulty eating adequately.

Describe the change itself as well. More hairs in the shower, a parting that gradually widens and a newly discovered bare patch are different observations. Our overview of alopecia can help you describe them, while leaving diagnosis to an examination. Older photographs may sometimes show that thinning had already started before the gynaecological medication now under suspicion.

Reactive shedding can become apparent after a delay rather than during an illness or operation. The clinician might consider telogen effluvium, alongside other explanations. This term describes a disturbance of hair renewal; it does not automatically identify the anaesthetic, the most recently taken tablet or a painful episode as the cause of the shedding.

You do not need a perfect calendar. A few reliable dates, prescriptions and details of treatment changes provide a useful starting point. If you cannot remember whether shedding preceded a medicine, say so rather than reconstructing a certainty afterwards. Follow-up may help clarify that uncertainty, without delaying an examination of hair changes that are happening now.

Assess iron status rather than automatically taking supplements

Substantial menstrual blood loss can contribute to iron deficiency, but not everyone with endometriosis has heavy periods. Other causes of bleeding may coexist and need gynaecological assessment. According to the NHS, iron deficiency anaemia can cause tiredness, palpitations and breathlessness, with hair loss among its less common symptoms. Those symptoms alone cannot confirm that iron is low.

Goldberg and colleagues’ study, published in the journal’s 2025 volume, provides a specific finding. Of 251 participants attending two specialist Canadian centres with symptomatic endometriosis, 53.4% met the researchers’ definition of iron deficiency. Some did not report heavy menstrual bleeding. This selected clinical population should not be treated as representative of everyone living with endometriosis.

Crucially, the study measured neither shedding nor hair regrowth and did not test iron treatment. It cannot predict a hair benefit from supplementation for each individual. The authors also discuss how inflammation can affect ferritin interpretation, sometimes making other information, including transferrin saturation, useful. This is a clinical interpretation issue, rather than a set of investigations to order independently.

When a deficiency is established, its origin needs investigation alongside appropriate correction. Choosing an online ferritin target as a personal regrowth goal can instead lead to unnecessary treatment. Bring earlier results with their dates and details of supplements already taken. Your clinician can then separate iron stores, possible anaemia and the dermatological question, which do not all provide the same information.

If periods are heavy, describe the practical impact: very frequent changes of sanitary protection, waking at night or cancelling activities. Even an approximate account can help, although it cannot measure your iron level. Conversely, having no obvious bleeding does not exclude a deficiency by itself. Fatigue may also have several contributors, so an isolated laboratory result should not automatically explain every continuing symptom.

A medicine may contribute without all treatments sharing that risk

Medicines used for endometriosis have different purposes and safety profiles. Their effect on pain or bleeding cannot predict how your hair will respond. Investigating a possible adverse effect requires the exact medicine, preparation and date of introduction. The general description “hormonal treatment” is not specific enough to establish either the risk or the appropriate next step.

Dienogest offers a documented example. The French official patient leaflet examined here, updated in November 2025, lists hair loss as a common adverse effect of that preparation. This supports discussing the possibility with the prescriber; it does not establish the cause of your shedding. The information concerns a particular medicine and cannot assign the same risk to every progestogen or contraceptive.

The leaflet also warns that prolonged heavy uterine bleeding can cause anaemia, alongside other precautions related to medical history. Report a change in bleeding rather than considering it only through its possible effect on hair. Follow the urgent safety instructions in the leaflet supplied with your own medicine, including those concerning sudden chest pain or sudden breathlessness. Such symptoms need immediate medical attention, not a routine hair appointment.

Do not stop treatment as an experiment for isolated shedding. Contact the prescriber and explain how the hair changes affect your life. Decisions need to consider symptom relief, suspected adverse effects and possible alternatives together. The dienogest leaflet notes that endometriosis symptoms may return after discontinuation, so the amount of hair found in a brush cannot determine the decision on its own.

Which changes warrant another appointment?

Arrange an assessment whenever the shedding concerns you or your hair changes noticeably. You do not have to wait for a large bare area or a distant gynaecology appointment. Your GP can begin the assessment and request dermatology input when the distribution of hair loss, the condition of the skin or its progression requires more specialised examination.

Mention a new patch, eyebrow loss, painful skin, redness or crusting. These findings do not identify alopecia areata or another particular condition on their own, but they give reasons to examine the scalp. Endometriosis should not prevent investigation of an independent skin disorder, even if a nutritional explanation initially seemed plausible or another cause of shedding has already been considered.

Also contact your clinician if bleeding becomes unusual, tiredness increases or you become breathless during activities you previously managed comfortably. These changes concern general health as well as appearance. Severe or sudden symptoms, such as feeling faint with substantial bleeding, require urgent assessment. Do not wait for a cosmetic appointment to discuss a potentially significant change in your physical health.

If pelvic pain or menstrual problems have never been investigated, describe them separately. A consultation about hair may identify a need for gynaecological advice, without making shedding a test for endometriosis. Equally, receiving good ongoing endometriosis care does not remove the need to assess new scalp symptoms or a hair change that no longer fits the original explanation.

Organise investigations around specific questions

A hair appointment starts with assessment of the distribution of hair and the condition of the scalp. A dermatologist may use magnification to examine the shafts and skin more closely. This helps distinguish recent shedding from longstanding thinning or a localised disorder, including situations in which more than one process contributes to what you have noticed.

Blood investigations then address the possibilities raised by the assessment. A clinician may request a full blood count to investigate anaemia and iron studies to clarify the available stores. Other tests depend on symptoms and medical history. An endometriosis diagnosis does not automatically require measurements of every hormone, vitamin and transport protein as part of a universal hair loss panel.

Ask how a proposed result would change care. An investigation of bleeding cannot replace a scalp examination, and reassuring blood results do not make your concern imaginary. When an abnormality is found, its significance, origin and monitoring still need discussion. It should not automatically be assigned responsibility for the whole set of symptoms simply because it appears outside a reference interval.

Collect reports already available and establish who is following each problem. Your gynaecologist can explain the purpose of treatment while a dermatologist clarifies the hair diagnosis. A written account of the main explanation, remaining uncertainties and next step can help maintain continuity. This becomes particularly useful when appointments are spaced apart or more than one service is involved.

You can ask whether the findings suggest one problem or several, and whom to contact if something changes. Worsening bleeding should reach the prescriber even when a dermatology appointment is booked for later. Conversely, a new bare patch need not wait for an iron review. Clear responsibilities help prevent a concern from remaining unanswered because each appointment focuses on a different part of care.

Match care to the problem that has been identified

A confirmed deficiency, a suspected adverse drug effect and persistent pattern thinning do not call for identical treatment. Correcting a deficit addresses a medical need but may be insufficient if another hair condition coexists. The plan can therefore include separate goals, with an identified clinician responsible for reviewing each one and explaining what progress would mean.

When discussing a gynaecological prescription, mention any pregnancy plans and your contraceptive needs. Medication taken for endometriosis is not necessarily a contraceptive: the dienogest leaflet explicitly makes that distinction. Clarify this before any change in treatment. Rare or absent periods cannot establish that you are protected against pregnancy, and a hair concern should not lead to an unplanned gap in care.

A dermatological treatment may be considered when the diagnosis supports it, after reviewing its particular precautions. There is no single hair prescription suitable for everyone with endometriosis. Ask about the intended outcome, adverse effects to watch for and when treatment will be reviewed. Starting several products together makes it harder to understand which, if any, is helping or causing irritation.

An injection programme, device or procedure described as “hormonal” deserves the same questions. Testimonials from people with endometriosis cannot establish effectiveness for your type of hair loss. Our hair transplant guide also distinguishes the principles of a procedure from medical management. That distinction is useful before making a booking or committing to a course of treatment.

Protect everyday comfort without adding unnecessary demands

Pain and digestive symptoms may make meals and familiar routines difficult. Discuss those practical barriers rather than independently adopting an exclusion diet intended to treat both endometriosis and hair loss. The aim is adequate nourishment and appropriate support when eating becomes restricted. No individual food can be selected on the promise that it will restore your former hair volume.

If iron has been prescribed, report troublesome constipation, nausea or abdominal discomfort. The NHS describes these possible effects and explains that follow-up may include repeat blood tests. Do not add several iron-containing supplements to an existing prescription. Ask your GP or pharmacist to review the products together, particularly if their ingredients overlap or digestive effects make treatment difficult to continue.

For styling, choose what feels comfortable and remains manageable. A different haircut or a wig may meet an immediate appearance concern while investigations continue, without changing the underlying cause. There is no obligation to conceal hair loss. Irritation from a product should be reported rather than endured in the hope that discomfort means it is stimulating growth.

Distress about your hair can also be discussed even when pelvic pain seems more urgent. Psychological support does not imply that the shedding is imagined or simply caused by anxiety. It can help you maintain activities, relationships and a sense of yourself while the medical questions are assessed. Your concern deserves attention alongside, rather than only after, the other demands of the condition.

Review progress without promising a regrowth deadline

Pain relief, improved blood results and changes in your hair do not necessarily happen on the same timetable. Agree a review appointment and what will be compared: shedding, coverage, scalp symptoms and treatment tolerability. Improvement in one area does not establish that every contributor has been identified, nor does it specify when the others should improve.

A few photographs taken under comparable conditions can support that discussion. Different lighting, a moved parting or wet hair can substantially alter how visible the scalp looks. These pictures document a trend with your clinician rather than independently confirming a hormonal cause. They do not replace an examination when a new area loses hair or the scalp becomes uncomfortable.

Continuing shedding may lead to reconsidering the diagnosis or investigating another contributor. It does not necessarily mean that endometriosis is worsening or that you have failed to follow advice. There needs to be room to discuss disappointing results and the burden of treatment without automatically being directed towards a more expensive procedure or another unsupported promise.

Review may support keeping a prescription that relieves endometriosis while addressing the hair separately, or discussing an alternative when its disadvantages become too difficult. Your priorities and medical risks matter alongside appearance. You can say that a hair effect is hard to live with even when treatment helps pain. That information belongs in the decision and should not be dismissed.

A transplant addresses a different question from endometriosis care

Endometriosis alone is not an indication for hair transplantation. Moving follicles cannot correct iron deficiency, remove an adverse drug effect or treat gynaecological lesions. Unexplained or changing hair loss needs assessment first. Choosing a particular implantation technique does not remove that need or establish that a procedure will be suitable for your circumstances.

If lasting hair loss compatible with surgery is eventually identified, assessment must consider the donor supply, realistic coverage and general health. Gynaecological medication and any pregnancy plans are relevant information for the medical team. Selecting DHI implantation does not replace this process and does not turn the procedure into a specific treatment for endometriosis.

For a proposed hair transplant in Istanbul, Body Expert offers English-speaking support to help prepare discussions around your medical history. This comes after assessment of the hair problem. Continuing medical care, postponing a decision or deciding against a procedure may remain appropriate outcomes, depending on the findings and your preferences.

Sources

Agence nationale de sécurité du médicament et des produits de santé. (2025, November 21). Dienogest Laboratoires Majorelle 2 mg, comprimé: Notice patient. Base de données publique des médicaments. Official French patient leaflet.

Goldberg, H. R., McCaffrey, C., Solnik, J., Lemos, N., Sobel, M., Kives, S., Malinowski, A. K., Shehata, N., Matelski, J., Szczech, K., & Murji, A. (2025). High prevalence of undiagnosed iron deficiency in endometriosis patients: A cross-sectional study. International Journal of Gynecology & Obstetrics, 168(3), 1321–1327. Full text.

NHS. (2024a, August 27). Endometriosis. NHS information.

NHS. (2024b, January 24). Hair loss. NHS information.

NHS. (2024c, January 26). Iron deficiency anaemia. NHS information.

Sakiyama, P. H., de Castro, C. C. S., Marchioro, H. Z., Gobo, C. G., Linhares, F. S., & Miot, H. A. (2025). Prevalence of skin diseases in women with endometriosis: A cross-sectional study. International Journal of Women’s Dermatology, 11(1), e195. Full text.